Key facts
- Inato’s last known valuation is $91.1M.
- It has raised $53.1M; the latest was Later Stage VC ($14.9M) in Dec 2024.
- Notable investors include Kima Ventures, Cathay Innovation, Cathay Capital, Elaia Partners, Obvious Ventures — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Inato
- ·The full record, as it builds
Funding rounds
No funding rounds for Inato are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inato
Operator of a global clinical trial marketplace intended to unlock trial access to patients globally and make clinical research inclusive and efficient. The company connects global pharmaceutical companies with a broader range of community research sites while ensuring reliable performance through collaborative enrollment planning and ongoing support, and ensuring that sites are successfully delivering trials, enabling doctors to get a tool to discover untapped research sites efficiently to select the right opportunities for them.
- Sector
- Information Technology
- HQ
- Guilford, CT, United States
- Founded
- 2016
- Employees
- 78
- Website
- inato.com/
- Ownership
- Privately Held (backing)
Inato doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inato shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inato in its N-PORT filings yet. We sweep new filings monthly.